UCB - Current Liabilities


UCB reported EUR4.4B in Current Liabilities for its fiscal semester ending in December of 2025.





Current Liabilities Change Date
Alcon AG USD 3.17B 163M Jun/2026
Almirall EUR 323.65M 26.99M Jun/2026
Amarin USD 175.14M 10.94M Sep/2026
argenx SE USD 1.58B 254.81M Jun/2026
AstraZeneca USD 31.27B 286M Sep/2026
Bayer EUR 29.4B 2.87B Sep/2026
Genmab DKK 1.14B 38M Jun/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
GRIFOLS EUR 2.3B 59M Sep/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Lakefront Biotherapeutics EUR 70.32M 30.1M Jun/2026
Lonza CHF 3.57B 421M Dec/2025
Merck EUR 8.96B 833M Sep/2026
Novartis USD 32.52B 777M Sep/2026
Orion EUR 491.8M 37.3M Sep/2026
Recordati EUR 1.4B 4.3M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 29.77B 2.16B Sep/2026
UCB EUR 4.4B 470M Dec/2025
Unibail Rodamco EUR 3.13B 2.32B Dec/2025